[ad_1]
AstraZeneca is disappointed to announce a planned reduction in the supply of COVID-19 to the European Union (EU), although it has worked tirelessly to accelerate the supply, the company said in a statement.
The company had previously warned that it would have to reduce the supply of the COVID-19 vaccine to Europe due to “lower than expected production process yields.”
This deficiency was expected to be partially compensated through the company’s global supply chain. In this way, it was expected to provide half of the doses of vaccine needed in the EU in the second quarter, in addition to 10 million. doses during the first trimester.
“Unfortunately, export restrictions will reduce supply in the first quarter and are likely to affect supply in the second quarter,” added AstraZeneca.
AstraZeneca began supplying its vaccine to the European Union in February and expects to deliver 100 million in the first half of this year. dose. Of these, 30 million. doses were to be administered in the first trimester.
The company said it was “working with the European Commission and member states to address supply challenges.”
“He remains convinced that productivity in the EU supply chain will continue to improve and help protect millions of Europeans from the virus,” the report said.
[ad_2]
